Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- PMID: 36603169
- DOI: 10.1200/JCO.22.02331
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
Erratum in
-
Erratum: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.J Clin Oncol. 2023 May 1;41(13):2454. doi: 10.1200/JCO.23.00441. Epub 2023 Mar 20. J Clin Oncol. 2023. PMID: 36940393 No abstract available.
Abstract
Purpose: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer.
Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
Results: Eighteen randomized controlled trials met the inclusion criteria for the systematic review.
Recommendations: For human epidermal growth factor receptor 2 (HER2)-negative patients with gastric adenocarcinoma (AC) and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥ 5, first-line therapy with nivolumab and chemotherapy (CT) is recommended. For HER2-negative patients with esophageal or gastroesophageal junction (GEJ) AC and PD-L1 CPS ≥ 5, first-line therapy with nivolumab and CT is recommended. First-line therapy with pembrolizumab and CT is recommended for HER2-negative patients with esophageal or GEJ AC and PD-L1 CPS ≥ 10. For patients with esophageal squamous cell carcinoma and PD-L1 tumor proportion score ≥ 1%, nivolumab plus CT, or nivolumab plus ipilimumab is recommended; for patients with esophageal squamous cell carcinoma and PD-L1 CPS ≥ 10, pembrolizumab plus CT is recommended. For patients with HER2-positive gastric or GEJ previously untreated, unresectable or metastatic AC, trastuzumab plus pembrolizumab is recommended, in combination with CT. For patients with advanced gastroesophageal or GEJ AC whose disease has progressed after first-line therapy, ramucirumab plus paclitaxel is recommended. For HER2-positive patients with gastric or GEJ AC who have progressed after first-line therapy, trastuzumab deruxtecan is recommended. In all cases, participation in a clinical trial is recommended as it is the panel's expectation that targeted treatment options for gastroesophageal cancer will continue to evolve.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
Similar articles
-
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.Eur J Cancer. 2022 Nov;176:13-29. doi: 10.1016/j.ejca.2022.08.023. Epub 2022 Sep 29. Eur J Cancer. 2022. PMID: 36183651 Review.
-
Immunotherapy in Gastric Cancer.Curr Oncol. 2022 Mar 2;29(3):1559-1574. doi: 10.3390/curroncol29030131. Curr Oncol. 2022. PMID: 35323331 Free PMC article. Review.
-
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.Nat Med. 2024 Jul;30(7):1943-1951. doi: 10.1038/s41591-024-03007-5. Epub 2024 May 22. Nat Med. 2024. PMID: 38778212 Clinical Trial.
-
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17. Oncologist. 2019. PMID: 30120163 Free PMC article.
-
Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.Cancer Immunol Immunother. 2024 Jun 4;73(8):144. doi: 10.1007/s00262-024-03721-6. Cancer Immunol Immunother. 2024. PMID: 38832979 Free PMC article.
Cited by
-
A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects.Sci Rep. 2024 Aug 9;14(1):18484. doi: 10.1038/s41598-024-66531-x. Sci Rep. 2024. PMID: 39122747
-
Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.Eur J Clin Pharmacol. 2024 Aug 5. doi: 10.1007/s00228-024-03734-1. Online ahead of print. Eur J Clin Pharmacol. 2024. PMID: 39102039
-
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.Gastric Cancer. 2024 Sep;27(5):1058-1068. doi: 10.1007/s10120-024-01518-1. Epub 2024 Jul 2. Gastric Cancer. 2024. PMID: 38954176 Free PMC article.
-
Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials.Cancers (Basel). 2024 Jun 14;16(12):2223. doi: 10.3390/cancers16122223. Cancers (Basel). 2024. PMID: 38927928 Free PMC article.
-
Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.Front Pharmacol. 2024 May 15;15:1225076. doi: 10.3389/fphar.2024.1225076. eCollection 2024. Front Pharmacol. 2024. PMID: 38813103 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous